Paul LaViolette has pointed to the Teijin-backed Ximedica structure as a possible new model for medtech venture investing, one that combines startup funding with market access and product-development support, and he has pushed portfolio companies to design for both the U.S. and Japanese markets from the start, given Japan's size as a device market. He also chaired the Medical Device Manufacturers Association and led all three major policy committees during a decade on AdvaMed's board, and he is often described as someone who has watched medtech evolve since its early days, from close work with interventionalists to major deals like Boston Scientific's acquisition of Guidant, giving him a long view of the industry alongside his current investing work.